Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was purchased at an average price of $19.58 per share, with a total value of $979,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Xencor, Inc. (NASDAQ:XNCR) opened at $20.42 on Tuesday. Xencor, Inc. has a 1-year low of $18.55 and a 1-year high of $29.38.
TRADEMARK VIOLATION WARNING: This piece was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.truebluetribune.com/2017/11/14/insider-buying-xencor-inc-xncr-major-shareholder-buys-979000-00-in-stock.html.
XNCR has been the subject of a number of recent research reports. Canaccord Genuity set a $36.00 price target on shares of Xencor and gave the stock a “buy” rating in a research note on Monday, October 23rd. BidaskClub downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies restated a “buy” rating and set a $35.00 price objective on shares of Xencor in a research report on Sunday. Finally, Zacks Investment Research downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Saturday. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Xencor currently has a consensus rating of “Hold” and an average target price of $30.25.
Several institutional investors have recently made changes to their positions in XNCR. Equitec Specialists LLC acquired a new position in shares of Xencor in the 2nd quarter valued at $116,000. Great West Life Assurance Co. Can increased its holdings in shares of Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares during the period. SG Americas Securities LLC increased its holdings in shares of Xencor by 62.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 3,252 shares during the period. Legal & General Group Plc increased its holdings in shares of Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the period. Finally, Principal Financial Group Inc. acquired a new position in shares of Xencor in the 3rd quarter valued at $201,000. 76.70% of the stock is currently owned by institutional investors and hedge funds.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.